EFIPLADIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C40H35Cl3N2O4S
Molecular Weight	746.141
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=C(CCCC2=C(CCNS(=O)(=O)CC3=CC=C(Cl)C(Cl)=C3)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=C(Cl)C=C26)C=C1

InChI

InChIKey=HIZOPJQOPKRKFM-UHFFFAOYSA-N

InChI=1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18498150 | https://www.ncbi.nlm.nih.gov/pubmed/21146550 | https://adisinsight.springer.com/drugs/800020059 | https://www.ncbi.nlm.nih.gov/pubmed/26416244 | https://www.ncbi.nlm.nih.gov/pubmed/25365190

Efipladib is an inhibitor of cytosolic phospholipase A2 alpha both in vitro and in vivo. It is able to relieve inflammatory pain in animal model. Additionally, efipladib exerts antitumor potential. Efipladib was in clinical trials for the treatment of asthma and arthritis however its development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
UniProtKB - Q6IRF5 (Q6IRF5_RAT) 1 Target ID: UniProtKB - Q6IRF5 (Q6IRF5_RAT) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18498150	Inhibitor 8297		0.07 µM [IC50]

PubMed

Title	Date	PubMed

Patents

Name

Type

Language

EFIPLADIB

Official Name

English

4-[3-[5-Chloro-2-[2-[[(3,4-dichlorobenzyl)sulfonyl]amino]ethyl]-1-(diphenylmethyl)-1H-indol-3-yl]propyl]benzoic acid

Common Name

English

PLA-902

Code

English

EFIPLADIB [USAN]

Common Name

English

efipladib [INN]

Common Name

English

BENZOIC ACID, 4-(3-(5-CHLORO-2-(2-((((3,4-DICHLOROPHENYL)METHYL)SULFONYL)AMINO)ETHYL)-1-(DIPHENYLMETHYL)-1H-INDOL-3-YL)PROPYL)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257